No entity in healthcare should have a blank check, but that's the current situation with specialty drugs, said Karen Ignagni, president and chief executive officer of America's Health Insurance Plans.
No entity in healthcare should have a blank check, but that’s the current situation with specialty drugs, said Karen Ignagni, president and chief executive officer of America’s Health Insurance Plans.
Her association has been trying to create a dialogue with pharmaceutical companies to find a way for greater transparency in pricing.
“We want to create sustainable innovation,” she said. “There’s no question. Every American wants that. But at the same time we’re not going to be able to create sustainable innovation unless we have such sustainable pricing.”
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More